Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells

The major mechanism of imatinib (IM) resistance of CML is the reactivation of ABL kinase either through BCR‐ABL gene amplification or mutation. We investigated the cytotoxicity of a pan‐ABL tyrosine kinase inhibitor, ponatinib, and a pan‐histone deacetylase inhibitor, panobinostat, against IM‐resist...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Matsuda, Yasufumi, Yamauchi, Takahiro, Hosono, Naoko, Uzui, Kanako, Negoro, Eiju, Morinaga, Koji, Nishi, Rie, Yoshida, Akira, Kimura, Shinya, Maekawa, Taira, Ueda, Takanori
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2016
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946706/
https://ncbi.nlm.nih.gov/pubmed/27166836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12965
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk